Rainer Kramer joined Immatics Biotechnologies GmbH in April 2012 from Signature Diagnostics AG where he was member of the Management Board and Chief Business Officer. He is responsible for Immatics’ corporate business development activities, intellectual property and strategic alliances.
During his career, he has delivered numerous strategic partnerships and license deals encompassing technology and product deals as well as equity transactions with an aggregate value of more than $3 billion. During the sale of Jerini to Shire in 2008 he was a member of Jerini’s M&A committee and Shire’s appointed principal for the sale of Jerini’s spin out of JPT Peptide Technologies GmbH in 2009. Rainer Kramer has worked in research and business development functions with increasing responsibilities at Amgen Inc., MorphoSys AG, Jerini AG, Shire PLC and Signature Diagnostics AG.
Rainer Kramer holds a Ph.D. from the Max-Planck-Institute for Neurobiology, Martinsried, Germany.